MITIGO- morphine sulfate injection Piramal Critical Care, Inc.----------

HIGHLIGHTS OF PRESCRIBING INFORMATIONMITIGO (Morphine Sulfate Injection, USP - Preservative-free)

These highlights do not include all the information needed to use MITIGO safely andeffectively. See full prescribing information for MITIGO.

MITIGO (morphine sulfate injection, USP - Preservative-free) injectible solution forintrathecal or epidural infusion, using a continuous microinfusion device, CII

Initial U.S. Approval: 1941

WARNING: RISKS WITH NEURAXIAL ADMINISTRATION; LIFE-THREATENING RESPIRATORYDEPRESSION;

RISK OF ADDICTION, ABUSE, AND MISUSE; NEONATAL OPIOID WITHDRAWALSYNDROME; and RISKS FROM CONCOMITANT USE WITH BENZODIAZEPINES OR OTHER

CNS DEPRESSANTSSee full prescribing information for complete boxed warning.

Single-dose neuraxial administration may result in acute or delayed respiratorydepression up to 24 hours. Because of the risk of severe adverse reactions whenMITIGO is administered by the epidural or intrathecal route of administration,patients must be observed in a fully equipped and staffed environment for at least24 hours after the initial dose [see Warnings and Precautions (5.1)].Serious, life-threatening, or fatal respiratory depression may occur. Monitor closely,especially upon initiation or following a dose increase. Patients must be observed ina fully equipped and staffed environment for at least 24 hours after each test doseand, as indicated, for the first several days after surgery. (5.2)MITIGO exposes users to risks of addiction, abuse, and misuse, which can lead tooverdose and death. Assess patient's risk before prescribing and monitor regularlyfor these behaviors and conditions. (5.3)Prolonged use of MITIGO during pregnancy can result in neonatal opioid withdrawalsyndrome, which may be life-threatening if not recognized and treated. If prolongedopioid use is required in a pregnant woman, advise the patient of the risk ofneonatal opioid withdrawal syndrome and ensure that appropriate treatment will beavailable. (5.4)Concomitant use of opioids with benzodiazepines or other central nervous system(CNS) depressants, including alcohol, may result in profound sedation, respiratorydepression, coma, and death. Reserve concomitant prescribing for use in patientsfor whom alternative treatment options are inadequate; limit dosages and durationsto the minimum required; and follow patients for signs and symptoms of respiratorydepression and sedation. (5.5, 7)

INDICATIONS AND USAGEMITIGO (Morphine Sulfate Injection, USP – Preservative-free) is an opioid agonist, for use in continuousmicroinfusion devices and indicated only for intrathecal or epidural infusion in the management ofintractable chronic pain severe enough to require an opioid analgesic and for which alternative treatmentsare inadequate. ( 1)

DOSAGE AND ADMINISTRATIONAdministration should be limited to use by those familiar with the management of respiratorydepression. ( 2.1)Should be administered by or under the direction of a physician experienced in the techniques ofepidural or intrathecal administration. ( 2.1)Patients should be observed in a fully equipped and staffed environment for at least 24 hours aftereach test dose and, as indicated, for the first several days after surgery. ( 2.1)Use the lowest effective dose for the shortest duration consistent with individual patient treatment

Use the lowest effective dose for the shortest duration consistent with individual patient treatmentgoals. ( 2.2)Individualize dosing based on the severity of pain, patient response, prior analgesic experience, and riskfactors for addiction, abuse, and misuse. ( 2.2)Initial Dosage: Must be individualized, based upon in-hospital evaluation of the response to serial single-dose epidural bolus injections of regular morphine sulfate injection, USP 0.5 mg/mL or 1 mg/mL, withclose observation for analgesic efficacy and adverse effects prior to surgery involving the continuousmicroinfusion device. ( 2.2)Dosage for Epidural Administration: Initial dose range of 3.5 to 7.5 mg/day for patients with no toleranceto opioids. The usual starting dose for continuous epidural infusion in patients with some degree ofopioid tolerance is 4.5 to 10 mg/day and may increase significantly during treatment to 20-30 mg/day. (2.3)Dosage for Intrathecal Administration: Initial dose range of 0.2 to 1 mg/day for patients with notolerance to opioids. The range of doses for patients with some degree of opioid tolerance varies from 1to 10 mg/day. Doses above 20 mg/day should be employed with caution. ( 2.4)Do not stop MITIGO abruptly in a physically dependent patient. ( 2.6)

DOSAGE FORMS AND STRENGTHSInjection: 200 mg/20 mL (10 mg/mL) Preservative-free amber glass single-dose vialsInjection: 500 mg/20 mL (25 mg/mL) Preservative-free amber glass single-dose vials ( 3)

CONTRAINDICATIONSSignificant respiratory depression ( 4)Acute or severe bronchial asthma in an unmonitored setting in absence of resuscitative equipment ( 4)Concurrent use of monoamine oxidase inhibitors (MAOIs) or use of MAOIs within the last 14 days ( 4)Known or suspected gastrointestinal obstruction, including paralytic ileus ( 4)Hypersensitivity or intolerance to morphine ( 4)

Neuraxial administration of MITIGO is contraindicated in patients with:Infection at the injection microinfusion site ( 4)Concomitant anticoagulant therapy ( 4)Uncontrolled bleeding diathesis ( 4)The presence of any other concomitant therapy or medical condition which would render epidural orintrathecal administration of medication especially hazardous. ( 4)

WARNINGS AND PRECAUTIONSRisk of Inflammatory Masses: Monitor patients receiving continuous infusion of MITIGO via indwellingintrathecal catheter for new signs or symptoms of neurologic impairment. ( 5.6)Risk of Tolerance and Myoclonic Activity: Monitor patients for unusual acceleration of neuraxialmorphine, which may cause myoclonic-like spasm of lower extremities. Detoxification may be required.( 5.7)Life-Threatening Respiratory Depression in Patients with Chronic Pulmonary Disease or in Elderly,Cachectic, or Debilitated Patients: Monitor closely, particularly during initiation and titration. ( 5.8)Adrenal Insufficiency: If diagnosed, treat with physiologic replacement of corticosteroids, and weanpatient off of the opioid. ( 5.10)Severe Hypotension: Monitor during dosage initiation and titration. Avoid use of MITIGO in patients withcirculatory shock. ( 5.11)Risks of Use in Patients with Increased Intracranial Pressure, Brain Tumors, Head Injury, or ImpairedConsciousness: Monitor for sedation and respiratory depression. Avoid use of MITIGO in patients withimpaired consciousness or coma. ( 5.12)

ADVERSE REACTIONSMost serious adverse reactions were respiratory depression, apnea, circulatory depression, respiratoryarrest, shock, and cardiac arrest. Other common frequently observed adverse reactions include: sedation,lightheadedness, dizziness, nausea, vomiting, and constipation. ( 6)To report SUSPECTED ADVERSE REACTIONS, contact Piramal Critical Care, Inc. at 1-888-822-8431 or FDA at 1-800-FDA-1088 or www.fda.gov/medwatch.

DRUG INTERACTIONSSerotonergic Drugs: Concomitant use may result in serotonin syndrome. Discontinue MITIGO ifserotonin syndrome is suspected. ( 7)Mixed Agonist/Antagonist and Partial Agonist Opioid Analgesics: Avoid use with MITIGO because theymay reduce the analgesic effect of MITIGO or precipitate withdrawal symptoms. ( 7)

USE IN SPECIFIC POPULATIONS

USE IN SPECIFIC POPULATIONSPregnancy: May cause fetal harm. ( 8.1)Hepatic and Renal Impairment: May affect the metabolism and excretion of MITIGO. ( 8.6)

See 17 for PATIENT COUNSELING INFORMATION.Revised: 7/2021

FULL PRESCRIBING INFORMATION: CONTENTS*WARNING: RISKS WITH NEURAXIAL ADMINISTRATION; LIFETHREATENINGRESPIRATORY DEPRESSION; RISK OF ADDICTION, ABUSE, AND MISUSE; NEONATAL OPIOID WITHDRAWALSYNDROME; and RISKS FROM CONCOMITANT USE WITH BENZODIAZEPINES OR OTHER CNS DEPRESSANTS1 INDICATIONS & USAGE2 DOSAGE AND ADMINISTRATION3 DOSAGE FORMS AND STRENGTHS4 CONTRAINDICATIONS5 WARNINGS AND PRECAUTIONS6 ADVERSE REACTIONS7 DRUG INTERACTIONS8 USE IN SPECIFIC POPULATIONS9 DRUG ABUSE AND DEPENDENCE10 OVERDOSAGE11 DESCRIPTION12 CLINICAL PHARMACOLOGY13 NONCLINICAL TOXICOLOGY16 HOW SUPPLIED/STORAGE AND HANDLING*

FULL PRESCRIBING INFORMATION

Sections or subsections omitted from the full prescribing information are not listed.

WARNING: RISKS WITH NEURAXIAL ADMINISTRATION;LIFETHREATENING RESPIRATORY DEPRESSION; RISK OF

ADDICTION, ABUSE, AND MISUSE; NEONATAL OPIOID WITHDRAWALSYNDROME; and RISKS FROM CONCOMITANT

USE WITH BENZODIAZEPINES OR OTHER CNS DEPRESSANTSBOXED WARNINGWARNING: RISKS WITH NEURAXIAL ADMINISTRATION; LIFE-THREATENINGRESPIRATORY DEPRESSION; RISK OF ADDICTION, ABUSE, AND MISUSE;NEONATAL OPIOID WITHDRAWAL SYNDROME; and RISKS FROMCONCOMITANT USE WITH BENZODIAZEPINES OR OTHER CNSDEPRESSANTSRisks with Neuraxial AdministrationBecause of the risk of severe adverse reactions when MITIGO isadministered by the epidural or intrathecal route of administration,patients must be observed in a fully equipped and staffed environmentfor at least 24 hours after the initial (single) test dose and, asappropriate, for the first several days after catheter implantation [seeWarnings and Precautions (5.1)].Life-Threatening Respiratory DepressionSerious, life-threatening, or fatal respiratory depression may occur withuse of MITIGO. Monitor for respiratory depression, especially duringinitiation of MITIGO or following a dose increase. Patients must beobserved in a fully equipped and staffed environment for at least 24hours after each test dose and, as indicated, for the first several daysafter surgery [see Warnings and Precautions (5.2)].Addiction, Abuse, and MisuseMITIGO exposes patients and other users to the risks of opioidaddiction, abuse, and misuse, which can lead to overdose and death.Assess each patient’s risk prior to prescribing MITIGO, and monitor allpatients regularly for the development of these behaviors andconditions [see Warnings and Precautions (5.3)].Neonatal Opioid Withdrawal SyndromeProlonged use of MITIGO during pregnancy can result in neonatal opioidwithdrawal syndrome, which may be life-threatening if not recognizedand treated, and requires management according to protocolsdeveloped by neonatology experts. If opioid use is required for aprolonged period in a pregnant woman, advise the patient of the risk ofneonatal opioid withdrawal syndrome and ensure that appropriatetreatment will be available [see Warnings and Precautions (5.4)].Risks From Concomitant Use With Benzodiazepines Or Other CNSDepressantsConcomitant use of opioids with benzodiazepines or other centralnervous system (CNS) depressants, including alcohol, may result in

profound sedation, respiratory depression, coma, and death [seeWarnings and Precautions (5.5), Drug Interactions (7)]

Reserve concomitant prescribing of MITIGO and benzodiazepines orother CNS depressants for use in patients for whom alternativetreatment options are inadequate.Limit dosages and durations to the minimum required.Follow patients for signs and symptoms of respiratory depression andsedation.

1 INDICATIONS & USAGEMITIGO is for use in continuous microinfusion devices and indicated only for intrathecalor epidural infusion in the management of intractable chronic pain severe enough torequire an opioid analgesic and for which less invasive means of controlling pain areinadequate.Limitations of UseNot for single-dose intravenous, intramuscular, or subcutaneous administration due tothe risk of overdose. Not for single-dose neuraxial injection because MITIGO is tooconcentrated for accurate delivery of the smaller doses used in this setting.

2 DOSAGE AND ADMINISTRATION2.1 Important Dosage and Administration InstructionsMITIGO should be administered by or under the direction of a physician experienced inthe techniques of epidural or intrathecal administration and familiar with the patientmanagement problems associated with epidural or intrathecal drug administration.

Because of the risk of delayed respiratory depression, patients should be observed ina fully equipped and staffed environment for at least 24 hours after each test doseand, as indicated, for the first several days after surgery.Because epidural administration has been associated with less potential for immediateor late adverse effects than intrathecal administration, the epidural route should beused whenever possible.For safety reasons, it is recommended that administration of MITIGO 200 mg/20 mLand 500 mg/20 mL (10 and 25 mg/mL, respectively) by the intrathecal route belimited to the lumbar area.MITIGO 200 mg/20 mL and 500 mg/20 mL (10 and 25 mg/ml, respectively) shouldnot be used for single-dose neuraxial injection because lower doses can be morereliably administered with the standard preparation of morphine sulfate injection, USP(0.5 and 1 mg/mL).

Candidates for neuraxial administration of MITIGO in a continuous microinfusion deviceshould be hospitalized to provide for adequate patient monitoring during assessment ofresponse to single doses of intrathecal or epidural morphine. Hospitalization should bemaintained for several days after surgery involving the infusion device for additionalmonitoring and adjustment of daily dosage. The facility must be equipped withresuscitative equipment, oxygen, naloxone injection and other resuscitative drugs.

A period of observation appropriate to the clinical situation should follow each refill ormanipulation of the drug reservoir. Before discharge, the patient and attendant(s)should receive instruction in the proper home care of the device and insertion site and inthe recognition and practical treatment of an overdose of neuraxial morphine.Familiarization with the continuous microinfusion device is essential. The desired amountof morphine should be withdrawn from the vial through a microfilter. To minimize riskfrom glass or other particles, the product must be filtered through a 5 µ (or smaller)microfilter before injecting into the microinfusion device. If dilution is required, 0.9%Sodium Chloride Injection is recommended.Reservoir filling must be performed by fully trained and qualified personnel, following thedirections provided by the device manufacturer. Care should be taken in selecting theproper refill frequency to prevent depletion of the reservoir, which would result inexacerbation of severe pain, onset of opioid withdrawal symptoms, and/or reflux ofcerebrospinal fluid into some devices. Strict aseptic technique is required to avoidbacterial contamination and serious infection. Extreme care must be taken to ensurethat the needle is properly inserted into the filling port of the device before attempting torefill the reservoir. Injecting the solution into the tissue around the device or (in the caseof devices that have more than one port) attempting to inject the refill dose into thedirect injection port will result in a large, clinically significant, overdosage to the patient.Safety and Handling Instructions:MITIGO is supplied in sealed vials. Accidental dermal exposure should be treated by theremoval of any contaminated clothing and rinsing the affected area with water.Inspect parenteral drug products for particulate matter before opening the amber vialsand again for color after removing contents from the vial. Do not use if the solution inthe unopened vial contains a precipitate which does not disappear upon shaking. Afterremoval, do not use unless the solution is colorless or pale yellow.MITIGO is intended for single-dose only. Protect from light, discard any unused portion.Do not heat-sterilize.2.2 Initial DosageThe starting dose of MITIGO must be individualized, based upon in-hospital evaluation ofthe response to serial single-dose epidural or intrathecal bolus injections of regularmorphine sulfate injection 0.5 mg/mL or 1 mg/mL, with close observation for analgesicefficacy and adverse effects prior to surgery involving the continuous microinfusiondevice.

Use the lowest effective dosage for the shortest duration consistent with individualpatient treatment goals [see Warnings and Precautions ( 5.3)].Initiate the dosing regimen for each patient individually, taking into account thepatient's severity of pain, patient response, prior analgesic treatment experience, andrisk factors for addiction, abuse, and misuse [see Warnings and Precautions ( 5.3)].Monitor patients closely for respiratory depression, especially within the first 24-72hours of initiating therapy and following dosage increases with MITIGO and adjust thedosage accordingly [see Warnings and Precautions ( 5.2)].

2.3 Dosage for Epidural AdministrationThe recommended initial epidural dose in patients who are not tolerant to opioids ranges

from 3.5 to 7.5 mg/day. The usual starting dose for continuous epidural infusion, basedupon limited data in patients who have some degree of opioid tolerance, is 4.5 to 10mg/day. The dose requirements may increase significantly during treatment, frequentlyto 20-30 mg/day. The upper daily limit for each patient must be individualized.2.4 Dosage for Intrathecal AdministrationThe recommended initial lumbar intrathecal dose range in patients with no tolerance toopioids is 0.2 to 1 mg/day. The published range of doses for individuals who have somedegree of opioid tolerance varies from 1 to 10 mg/day. The upper daily dosage limit foreach patient must be individualized.

Intrathecal dosage is usually 1/10 that of epidural dosage.

2.5 Titration and Maintenance of TherapyIndividually titrate MITIGO to a dose that provides adequate analgesia and minimizesadverse reactions. Continually reevaluate patients receiving MITIGO to assess themaintenance of pain control and the relative incidence of adverse reactions, as well asmonitoring for the development of addiction, abuse, or misuse [see Warnings andPrecautions ( 5.3)]. Frequent communication is important among the prescriber, othermembers of the healthcare team, the patient, and the caregiver/family during periods ofchanging analgesic requirements, including initial titration.If the level of pain increases after dosage stabilization, attempt to identify the source ofthe increased pain before increasing the MITIGO dosage. Limited experience withcontinuous intrathecal infusion of morphine has shown that the daily doses have to beincreased over time. Although the rate of increase, over time, in the dose required tosustain analgesia is highly variable, an estimate of the expected rate of increase isshown in the following Figure.

Doses above 20 mg/day should be employed with caution since they may be associatedwith a higher likelihood of serious side effects [see Warnings and Precautions ( 5.2, 5.7)and Adverse Reactions ( 6)].

If unacceptable opioid-related adverse reactions are observed, consider reducing thedosage. Adjust the dosage to obtain an appropriate balance between management ofpain and opioid-related adverse reactions.2.6 Discontinuation of MITIGOWhen a patient who has been taking MITIGO regularly and may be physically dependentno longer requires therapy with MITIGO, taper the dose gradually while monitoringcarefully for signs and symptoms of withdrawal. If the patient develops these signs orsymptoms, raise the dose to the previous level and taper more slowly, either byincreasing the interval between decreases, decreasing the amount of change in dose, orboth. Do not stop MITIGO abruptly in a physically-dependent patient [see Warnings andPrecautions ( 5.15), Drug Abuse and Dependence ( 9.3)].

3 DOSAGE FORMS AND STRENGTHS3 DOSAGE FORMS AND STRENGTHSInjection: 200 mg per 20 mL (10 mg/mL) Preservative-free amber glass single-dose vialsInjection: 500 mg per 20 mL (25 mg/mL) Preservative-free amber glass single-dose vials

4 CONTRAINDICATIONSMITIGO is contraindicated in patients with:

Significant respiratory depression [see Warnings and Precautions ( 5.2)]Acute or severe bronchial asthma in an unmonitored setting or in the absence ofresuscitative equipment [see Warnings and Precautions ( 5.8)]Concurrent use of monoamine oxidase inhibitors (MAOIs) or use of MAOIs within thelast 14 days [see Warnings and Precautions ( 5.9)/ Drug Interactions ( 7)]Known or suspected gastrointestinal obstruction, including paralytic ileus [seeWarnings and Precautions ( 5.13)]Hypersensitivity to morphine (e.g., anaphylaxis) [See Adverse Reactions ( 6)]

Neuraxial administration of MITIGO is contraindicated in patients with:Infection at the injection microinfusion site [see Warnings and Precautions ( 5.1)]Concomitant anticoagulant therapy [see Warnings and Precautions ( 5.1)]Uncontrolled bleeding diathesis [see Warnings and Precautions ( 5.1)]The presence of any other concomitant therapy or medical condition which wouldrender epidural or intrathecal administration of medication especially hazardous.

5 WARNINGS AND PRECAUTIONS5.1 Risks with Neuraxial AdministrationControl of pain by neuraxial opiate delivery, using a continuous microinfusion device, isalways accompanied by considerable risk to the patients and requires a high level of skillto be successfully accomplished. The task of treating these patients must be undertakenby experienced clinical teams, well-versed in patient selection, evolving technology andemerging standards of care.

MITIGO should be administered by or under the direction of a physician experienced inthe techniques of epidural or intrathecal administration and familiar with the patientmanagement problems associated with epidural or intrathecal drug administration. Thephysician should be familiar with patient conditions (such as infection at the injection site,bleeding diathesis, anticoagulant therapy, etc.) which call for special evaluation of thebenefit versus risk potential.Because of the risk of severe adverse effects when the epidural or intrathecal route ofadministration is employed, patients must be observed in a fully equipped and staffedenvironment for at least 24 hours after the initial dose.The facility must be equipped to resuscitate patients with severe opioid overdosage, andthe personnel must be familiar with the use and limitations of specific narcoticantagonists (naloxone, naltrexone) in such cases.For safety reasons, it is recommended that administration of MITIGO 200 mg/20 mL and500 mg/20 mL (10 and 25 mg/mL, respectively) by the intrathecal route be limited to thelumbar area.5.2 Life-Threatening Respiratory DepressionSerious, life-threatening, or fatal; respiratory depression has been reported with the useof opioids, even when used as recommended. Respiratory depression, if not immediatelyrecognized and treated, may lead to respiratory arrest and death. Management ofrespiratory depression may include close observation, supportive measures, and use ofopioid antagonists, depending on the patient’s clinical status [see Overdosage ( 10)].Carbon dioxide (CO2) retention from opioid-induced respiratory depression canexacerbate the sedating effects of opioids.While serious, life-threatening, or fatal respiratory depression can occur at any timeduring the use of MITIGO, the risk is greatest during the initiation of therapy or followinga dosage increase. This respiratory depression and/or respiratory arrest may be severeand could require intervention.

Because of the risk of severe adverse effects, patients must be observed in a fullyequipped and staffed environment for at least 24 hours after the initial (single) testdose and, as appropriate, for the first several days after catheter implantation. Thefacility must be equipped to resuscitate patients with severe opioid overdosage, andthe personnel must be familiar with the use and limitations of specific narcoticantagonists (naloxone, naltrexone) in such cases.Severe respiratory depression up to 24 hours following epidural or intrathecaladministration has been reported.Intrathecal use has been associated with a higher incidence of respiratory depressionthan epidural use.Parenteral administration of narcotics in patients receiving epidural or intrathecalmorphine may result in overdosage.

To reduce the risk of respiratory depression, proper dosing and titration of MITIGO areessential [see Dosage and Administration ( 2)]. Overestimating the MITIGO dosage whenconverting patients from another opioid product can result in a fatal overdose with thefirst dose.IMPROPER OR ERRONEOUS SUBSTITUTION OF MITIGO 200 mg/20 mL and 500 mg/20mL (10 or 25 mg/mL, respectively) FOR REGULAR MORPHINE SULFATE INJECTION (0.5

or 1 mg/mL) IS LIKELY TO RESULT IN SERIOUS OVERDOSAGE, LEADING TO SEIZURES,RESPIRATORY DEPRESSION, AND DEATH.Opioids can cause sleep-related breathing disorders including central sleep apnea (CSA)and sleep-related hypoxemia. Opioid use increases the risk of CSA in a dose-dependentfashion. In patients who present with CSA, consider decreasing the opioid dosage usingbest practices for opioid taper [see Dosage and Administration ( 2.6)].5.3 Addiction, Abuse, and MisuseMITIGO contains morphine, a Schedule II controlled substance. As an opioid, MITIGOexposes users to the risks of addiction, abuse, and misuse [see Drug Abuse andDependence ( 9)].Although the risk of addiction in any individual is unknown, it can occur in patientsappropriately prescribed MITIGO. Addiction can occur at recommended dosages and ifthe drug is misused or abused.Assess each patient’s risk for opioid addiction, abuse, or misuse prior to prescribingMITIGO, and monitor all patients receiving MITIGO for the development of thesebehaviors and conditions. Risks are increased in patients with a personal or familyhistory of substance abuse (including drug or alcohol abuse or addiction) or mentalillness (e.g., major depression). The potential for these risks should not, however,prevent the proper management of pain in any given patient. Patients at increased riskmay be prescribed opioids such as MITIGO, but use in such patients necessitatesintensive counseling about the risks and proper use of MITIGO along with intensivemonitoring for signs of addiction, abuse, and misuse.Opioids are sought by drug users and people with addiction disorders and are subject tocriminal diversion. Consider these risks when prescribing or dispensing MITIGO.Strategies to reduce these risks include prescribing the drug in the smallest appropriatequantity. Contact local state professional licensing board or state controlled substancesauthority for information on how to prevent and detect abuse or diversion of thisproduct.Each vial of MITIGO contains a large amount of a potent narcotic which has beenassociated with abuse and dependence among health care providers. Due to the limitedindications for this product, the risk of overdosage and the risk of its diversion andabuse, it is recommended that special measures must be taken to control this productwithin the hospital or clinic. MITIGO should be subject to rigid accounting, rigorouscontrol of wastage, and restricted access.5.4 Neonatal Opioid Withdrawal SyndromeProlonged use of MITIGO during pregnancy can result in withdrawal in the neonate.Neonatal opioid withdrawal syndrome, unlike opioid withdrawal syndrome in adults, maybe life-threatening if not recognized and treated, and requires management according toprotocols developed by neonatology experts. Observe newborns for signs of neonatalopioid withdrawal syndrome and manage accordingly. Advise pregnant women usingopioids for a prolonged period of the risk of neonatal opioid withdrawal syndrome andensure that appropriate treatment will be available [see Use in Specific Populations ( 8.1),Patient Counseling Information ( 17)].5.5 Risks from Concomitant Use with Benzodiazepines or Other CNSDepressants

Profound sedation, respiratory depression, coma, and death may result fromconcomitant use of MITIGO with benzodiazepines or other CNS depressants, (e.g., non-benzodiazepine sedatives/hypnotics, anxiolytics, tranquilizers, muscle relaxants, generalanesthetics, antipsychotics, other opioids, alcohol). Because of these risks, reserveconcomitant prescribing of these drugs for use in patients for whom alternativetreatment options are inadequate.Use of neuroleptics in conjunction with neuraxial morphine may increase the risk ofrespiratory depression.Observational studies have demonstrated that concomitant use of opioid analgesics andbenzodiazepines increases the risk of drug-related mortality compared to use of opioidanalgesics alone. Because of similar pharmacological properties, it is reasonable toexpect similar risk with the concomitant use of other CNS depressant drugs with opioidanalgesics [see Drug Interactions ( 7)].If the decision is made to prescribe a benzodiazepine or other CNS depressantconcomitantly with an opioid analgesic, prescribe the lowest effective dosages andminimum durations of concomitant use. In patients already receiving an opioid analgesic,prescribe a lower initial dose of the benzodiazepine or other CNS depressant thanindicated in the absence of an opioid, and titrate based on clinical response. If an opioidanalgesic is initiated in a patient already taking a benzodiazepine or other CNSdepressant, prescribe a lower initial dose of the opioid analgesic, and titrate based onclinical response. Follow patients closely for signs and symptoms of respiratorydepression and sedation.Advise both patients and caregivers about the risks of respiratory depression andsedation when MITIGO is used with benzodiazepines or other CNS depressants(including alcohol and illicit drugs). Advise patients not to drive or operate heavymachinery until the effects of concomitant use of the benzodiazepine or other CNSdepressant have been determined. Screen patients for risk of substance use disorders,including opioid abuse and misuse, and warn them of the risk for overdose and deathassociated with the use of additional CNS depressants including alcohol and illicit drugs[see Drug Interactions ( 7), Patient Counseling Information ( 17)].5.6 Risk of Inflammatory MassesInflammatory masses such as granulomas, some of which have resulted in seriousneurologic impairment including paralysis, have been reported to occur in patientsreceiving continuous infusion of opioid analgesics including MITIGO via indwellingintrathecal catheter. Patients receiving continuous infusion of MITIGO via indwellingintrathecal catheter should be carefully monitored for new neurologic signs orsymptoms. Further assessment or intervention should be based on the clinical conditionof the individual patient.5.7 Risk of Tolerance and Myoclonic ActivityPatients sometimes manifest unusual acceleration of neuraxial morphine requirements,which may cause concern regarding systemic absorption and the hazards of largedoses; these patients may benefit from hospitalization and detoxification. Two cases ofmyoclonic-like spasm of the lower extremities have been reported in patients receivingmore than 20 mg/day of intrathecal morphine. After detoxification, it might be possibleto resume treatment at lower doses, and some patients have been successfully

changed from continuous epidural morphine to continuous intrathecal morphine. Repeatdetoxification may be indicated at a later date. The upper daily dosage limit for eachpatient during continuing treatment must be individualized.5.8 Life-Threatening Respiratory Depression in Patients with ChronicPulmonary Disease or in Elderly, Cachectic, or Debilitated PatientsThe use of MITIGO in patients with acute or severe bronchial asthma in an unmonitoredsetting or in the absence of resuscitative equipment is contraindicated.Patients with Chronic Pulmonary Disease: Patients with significant chronic obstructivepulmonary disease or cor pulmonale, and those with a substantially decreasedrespiratory reserve, hypoxia, hypercapnia, or pre-existing respiratory depression are atincreased risk of decreased respiratory drive including apnea, even at recommendeddoses of MITIGO [see Warnings and Precautions ( 5.2)].Elderly, Cachectic, or Debilitated Patients: Life-threatening respiratory depression ismore likely to occur in elderly, cachectic, or debilitated patients because they may havealtered pharmacokinetics or altered clearance compared to younger, healthier patients[see Warnings and Precautions ( 5.2)].Monitor such patients closely, particularly when initiating and titrating MITIGO and whenMITIGO is given concomitantly with other drugs that depress respiration [see Warningsand Precautions ( 5.2)]. Alternatively, consider the use of non-opioid analgesics in thesepatients.5.9 Interaction with Monoamine Oxidase InhibitorsMonoamine oxidase inhibitors (MAOIs) may potentiate the effects of morphine, includingrespiratory depression, coma, and confusion. Morphine Sulfate Injection should not beused in patients taking MAOIs or within 14 days of stopping such treatment [see DrugInteractions ( 7)].5.10 Adrenal InsufficiencyCases of adrenal insufficiency have been reported with opioid use, more often followinggreater than one month of use. Presentation of adrenal insufficiency may include non-specific symptoms and signs including nausea, vomiting, anorexia, fatigue, weakness,dizziness, and low blood pressure. If adrenal insufficiency is suspected, confirm thediagnosis with diagnostic testing as soon as possible. If adrenal insufficiency isdiagnosed, treat with physiologic replacement doses of corticosteroids. Wean thepatient off of the opioid to allow adrenal function to recover and continue corticosteroidtreatment until adrenal function recovers. Other opioids may be tried as some casesreported use of a different opioid without recurrence of adrenal insufficiency. Theinformation available does not identify any particular opioids as being more likely to beassociated with adrenal insufficiency.5.11 Severe HypotensionMITIGO may cause severe hypotension including orthostatic hypotension and syncope inambulatory patients. There is increased risk in patients whose ability to maintain bloodpressure has already been compromised by a reduced blood volume or concurrentadministration of certain CNS depressant drugs (e.g., phenothiazines or generalanesthetics) [see Drug Interactions ( 7)]. Monitor these patients for signs ofhypotension after initiating or titrating the dosage of MITIGO. In patients with circulatory

shock, MITIGO may cause vasodilation that can further reduce cardiac output and bloodpressure. Avoid the use of MITIGO in patients with circulatory shock.5.12 Risks of Use in Patients with Increased Intracranial Pressure, BrainTumors, Head Injury, or Impaired ConsciousnessIn patients who may be susceptible to the intracranial effects of CO2 retention (e.g.,those with evidence of increased intracranial pressure or brain tumors), MITIGO mayreduce respiratory drive, and the resultant CO2 retention can further increaseintracranial pressure. Monitor such patients for signs of sedation and respiratorydepression, particularly when initiating therapy with MITIGO. MITIGO should be used withextreme caution in patients with head injury or increased intracranial pressure. Pupillarychanges (miosis) from morphine may obscure the existence, extent and course ofintracranial pathology. High doses of neuraxial morphine may produce myoclonic events[see Warnings and Precautions ( 5.7)]. Clinicians should maintain a high index ofsuspicion for adverse drug reactions when evaluating altered mental status ormovement abnormalities in patients receiving this modality of treatment.Opioids may also obscure the clinical course in a patient with a head injury. Avoid the useof MITIGO in patients with impaired consciousness or coma.5.13 Risks of Use in Patients with Gastrointestinal ConditionsMITIGO is contraindicated in patients with known or suspected gastrointestinalobstruction, including paralytic ileus.The morphine in MITIGO may cause spasm of the sphincter of Oddi. Opioids may causeincreases in serum amylase. Monitor patients with biliary tract disease, including acutepancreatitis for worsening symptoms. As significant morphine is released into thesystemic circulation from neuraxial administration, the ensuing smooth musclehypertonicity may result in biliary colic.5.14 Increased Risks of Seizures in Patients with Seizure DisordersThe morphine in MITIGO may increase the frequency of seizures in patients with seizuredisorders, and may increase the risk of seizures occurring in other clinical settingassociated with seizures. Monitor patients with a history of seizure disorders forworsened seizure control during MITIGO therapy.5.15 WithdrawalAvoid the use of mixed agonist/antagonist (e.g., pentazocine, nalbuphine, andbutorphanol) or partial agonist (e.g., buprenorphine) analgesics in patients, mixedagonist/antagonist and partial agonist analgesics, including MITIGO. In these patients,mixed agonist/antagonist and partial agonist analgesics may reduce the analgesic effectand/or precipitate withdrawal symptoms.When discontinuing MITIGO, gradually taper the dosage [see Dosage and Administration(2.6)]. Do not abruptly discontinue MITIGO [see Drug Abuse and Dependence ( 9.3)].5.16 Risk of Driving and Operating MachineryMITIGO may impair the mental or physical abilities needed to perform potentiallyhazardous activities such as driving a car or operating machinery. Warn patients not todrive or operate dangerous machinery unless they are tolerant to the effects of MITIGOand know how they will react to the medication [see Patient Counseling Information (

17)].5.17 Risks of Use in Patients with Urinary System DisordersUrinary retention, which may persist 10 to 20 hours following single epidural orintrathecal administration, is a frequently associated with neuraxial opioid administrationand must be anticipated, more frequently in male patients than female patients. Urinaryretention may also occur during the first several days of hospitalization for the initiationof continuous intrathecal or epidural morphine therapy. Early recognition of difficulty inurination and prompt intervention in cases of urinary retention is indicated. Patients whodevelop urinary retention have responded to cholinomimetic treatment and/or judicioususe of catheters.5.18 Risks of Use in Ambulatory PatientsPatients with reduced circulating blood volume, impaired myocardial function or onsympatholytic drugs should be monitored for the possible occurrence of orthostatichypotension, a frequent complication in single-dose neuraxial morphine analgesia.

6 ADVERSE REACTIONSThe following serious adverse reactions are described, or described in greater detail, inother sections:

Life-Threatening Respiratory Depression [see Warnings and Precautions ( 5.2)]Addiction, Abuse, and Misuse [see Warnings and Precautions ( 5.3)]Neonatal Opioid Withdrawal Syndrome [see Warnings and Precautions ( 5.4)]Interactions with CNS Benzodiazepines or Other Depressants [see Warnings andPrecautions ( 5.5)]Inflammatory Masses [see Warnings and Precautions ( 5.6)]Myoclonic Activity [see Warnings and Precautions ( 5.7)]Adrenal Insufficiency [see Warnings and Precautions ( 5.10)]Severe Hypotension [see Warnings and Precautions ( 5.11)]Gastrointestinal Adverse Reactions [see Warnings and Precautions ( 5.13)]Seizures [see Warnings and Precautions ( 5.14)]Withdrawal [see Warnings and Precautions ( 5.15)]Urinary Retention [see Warnings and Precautions ( 5.17)]Orthostatic Hypotension [see Warnings and Precautions ( 5.18)]

The following adverse reactions associated with the use of morphine were identified inclinical studies or postmarketing reports. Because some of these reactions werereported voluntarily from a population of uncertain size, it is not always possible toreliably estimate their frequency or establish a causal relationship to drug exposure.The most serious adverse reactions encountered during continuous intrathecal orepidural infusion of MITIGO were respiratory depression, myoclonus, and formation ofinflammatory masses.Cardiovascular System: While low doses of intravenously administered morphine havelittle effect on cardiovascular stability, high doses are excitatory, resulting fromsympathetic hyperactivity and increase in circulating catecholamines. Excitation of thecentral nervous system, resulting in convulsions, may accompany high doses ofmorphine given intravenously.

Central Nervous System: myoclonus, seizures, dysphoric reactions, toxic psychosis,dizziness, euphoria, anxiety, confusion, headache. Lumbar puncture-type headache isencountered in a significant minority of cases for several days following intrathecalcatheter implantation and generally responds to bed rest and/or other conventionaltherapy.Gastrointestinal System: Nausea, vomiting, constipation.Skin: Pruritus, urticaria, wheals, and/or local tissue irritation.Genitourinary System: Urinary retention, oliguria, unexplained genital swelling in malepatients, following infusion-device implant surgery.Other: Other adverse experiences reported following morphine therapy includedepression of cough reflex, interference with thermal regulation, peripheral edema.Serotonin syndrome: Cases of serotonin syndrome, a potentially life-threateningcondition, have been reported during concomitant use of opioids with serotonergicdrugs.Adrenal insufficiency: Cases of adrenal insufficiency have been reported with opioid use,more often following greater than one month of use.Anaphylaxis: Anaphylaxis has been reported with ingredients contained in MITIGO.Androgen deficiency: Cases of androgen deficiency have occurred with chronic use ofopioids [see Clinical Pharmacology ( 12.2)].

7 DRUG INTERACTIONSTable 1 includes clinically significant drug interactions with MITIGO.Table 1. Clinically Significant Drug Interactions with MITIGO

Benzodiazepines and Other Central Nervous System (CNS) Depressants

ClinicalImpact

Due to additive pharmacologic effect, the concomitant use ofbenzodiazepines or other CNS depressants, including alcohol, can increasethe risk of hypotension, respiratory depression, profound sedation, coma,and death. The depressant effects of morphine are potentiated by thepresence of other CNS depressants. Use of neuroleptics in conjunction withneuraxial morphine may increase the risk of respiratory depression.

InterventionReserve concomitant prescribing of these drugs for use in patients forwhom alternative treatment options are inadequate. Limit dosages anddurations to the minimum required. Follow patients closely for signs ofrespiratory depression and sedation [see Warnings and Precautions ( 5.5)].

ExamplesAlcohol, benzodiazepines and other sedatives/hypnotics, anxiolytics,tranquilizers, muscle relaxants, general anesthetics, antipsychotics,psychotropic drugs, antihistamines, neuroleptics, other opioids, alcohol.

Serotonergic DrugsClinicalImpact

The concomitant use of opioids with other drugs that affect theserotonergic neurotransmitter system has resulted in serotonin syndrome.

InterventionIf concomitant use is warranted, carefully observe the patient, particularlyduring treatment initiation and dose adjustment. Discontinue MITIGO if

serotonin syndrome is suspected.

Examples

Selective serotonin reuptake inhibitors (SSRIs), serotonin andnorepinephrine reuptake inhibitors (SNRIs), tricyclic antidepressants (TCAs),triptans, 5-HT3 receptor antagonists, drugs that effect the serotoninneurotransmitter system (e.g., mirtazapine, trazodone, tramadol), certainmuscle relaxants (i.e., cyclobenzaprine, metaxalone), monoamine oxidase(MAO) inhibitors (those intended to treat psychiatric disorders and alsoothers, such as linezolid and intravenous methylene blue).

Monoamine Oxidase Inhibitors (MAOIs)ClinicalImpact

MAOI interactions with opioids may manifest as serotonin syndrome oropioid toxicity (e.g., respiratory depression, coma) [see Warnings andPrecautions ( 5.9)].

Intervention

Do not use MITIGO in patients taking MAOIs or within 14 days of stoppingsuch treatment. If urgent use of an opioid is necessary, use test doses andfrequent titration of small doses of other opioids (such as oxycodone,hydrocodone, oxymorphone, hydrocodone, or buprenorphine) to treat painwhile closely monitoring blood pressure and signs and symptoms of CNSand respiratory depression.

Examples Phenelzine, tranylcypromine, linezolid.Mixed Agonist/Antagonist and Partial Agonist Opioid AnalgesicsClinicalImpact

May reduce the analgesic effect of MITIGO and/or precipitate withdrawalsymptoms.

InterventionAvoid concomitant use.Examples Butorphanol, nalbuphine, pentazocine, buprenorphine.Muscle RelaxantsClinicalImpact

Morphine may enhance the neuromuscular blocking action of skeletalmuscle relaxants and produce an increased degree of respiratorydepression.

InterventionMonitor patients for signs of respiratory depression that may be greaterthan otherwise expected and decrease the dosage of MITIGO and/or themuscle relaxant as necessary.

DiureticsClinicalImpact

Opioids can reduce the efficacy of diuretics by inducing the release ofantidiuretic hormone.

InterventionMonitor patients for signs of diminished diuresis and/or effects on bloodpressure and increase the dosage of the diuretic as needed.

Anticholinergic DrugsClinicalImpact

The concomitant use of anticholinergic drugs may increase risk of urinaryretention and/or severe constipation, which may lead to paralytic ileus.

InterventionMonitor patients for signs of urinary retention or reduced gastric motilitywhen MITIGO is used concomitantly with anticholinergic drugs.

Oral P2Y InhibitorsClinicalImpact

The co-administration of oral P2Y inhibitors and intravenous morphinesulfate can decrease the absorption and peak concentration of oral P2Y inhibitors, and delay the onset of the antiplatelet effect.

InterventionConsider the use of parenteral antiplatelet agent in the setting of acutecoronary syndrome requiring co-administration of intravenous morphinesulfate.

Examples Clopidogrel, prasugrel, ticagrelor

1212

12

8 USE IN SPECIFIC POPULATIONS8.1 PregnancyRisk SummaryProlonged use of opioid analgesics during pregnancy can cause neonatal opioidwithdrawal syndrome [see Warnings and Precautions ( 5.4)]. There are no available datawith MITIGO in pregnant women to inform a drug-associated risk for major birth defectsand miscarriage. Published studies with morphine use during pregnancy have notreported a clear association with morphine and major birth defects [see Human Data]. Inpublished animal reproduction studies, morphine administered subcutaneously duringthe early gestational period produced neural tube defects (i.e., exencephaly andcranioschisis) at 5 and 16 times the human daily dose of 60 mg based on body surfacearea (HDD) in hamsters and mice, respectively, lower fetal body weight and increasedincidence of abortion at 0.4 times the HDD in the rabbit, growth retardation at 6 timesthe HDD in the rat, and axial skeletal fusion and cryptorchidism at 16 times the HDD inthe mouse. Administration of morphine sulfate to pregnant rats during organogenesisand through lactation resulted in cyanosis, hypothermia, decreased brain weights, pupmortality, decreased pup body weights, and adverse effects on reproductive tissues at3-4 times the HDD; and long-term neurochemical changes in the brain of offspringwhich correlate with altered behavioral responses that persist through adulthood atexposures comparable to and less than the HDD [see Animal Data]. Based on animaldata, advise pregnant women of the potential risk to a fetus.The estimated background risk of major birth defects and miscarriage for the indicatedpopulation is unknown. All pregnancies have a background risk of birth defect, loss, orother adverse outcomes. In the U.S. general population, the estimated background riskof major birth defects and miscarriage in clinically recognized pregnancies is 2-4% and15-20%, respectively.Clinical ConsiderationsFetal/Neonatal Adverse Reactions

Prolonged use of opioid analgesics during pregnancy for medical or nonmedicalpurposes can result in physical dependence in the neonate and neonatal opioidwithdrawal syndrome shortly after birth.Neonatal opioid withdrawal syndrome presents as irritability, hyperactivity and abnormalsleep pattern, high pitched cry, tremor, vomiting, diarrhea, and failure to gain weight.The onset, duration, and severity of neonatal opioid withdrawal syndrome vary based onthe specific opioid used, duration of use, timing and amount of last maternal use, andrate of elimination of the drug by the newborn. Observe newborns for symptoms ofneonatal opioid withdrawal syndrome and manage accordingly [see Warnings andPrecautions ( 5.4)].Labor or Delivery

MITIGO 200 mg/20 mL and 500 mg/20 mL (10 and 25 mg/mL, respectively) are toohighly concentrated for routine use in obstetric neuraxial analgesia. Opioids, includingintravenously, epidurally, and intrathecally administered morphine, readily cross theplacenta and may produce respiratory depression and psychophysiological effects in

neonates. An opioid antagonist, such as naloxone, and resuscitative equipment must beavailable for reversal of opioid-induced respiratory depression in the neonate. MITIGO isnot recommended for use in pregnant women during or immediately prior to labor,when other analgesic techniques are more appropriate. Opioid analgesics, includingMITIGO, can prolong labor through actions which temporarily reduce the strength,duration, and frequency of uterine contractions. However, this effect is not consistentand may be offset by an increased rate of cervical dilation, which tends to shorten labor.Monitor neonates exposed to opioid analgesics during labor for signs of excess sedationand respiratory depression.DataHuman Data

The results from a population-based prospective cohort, including 70 women exposedto morphine during the first trimester of pregnancy and 448 women exposed tomorphine at any time during pregnancy, indicate no increased risk for congenitalmalformations. However, these studies cannot definitely establish the absence of anyrisk because of methodological limitations, including small sample size and non-randomized study design.Animal Data

Formal reproductive and developmental toxicology studies for morphine have not beenconducted. Exposure margins for the following published study reports are based onhuman daily dose of 60 mg morphine using a body surface area comparison (HDD).Neural tube defects (exencephaly and cranioschisis) were noted following subcutaneousadministration of morphine sulfate (35-322 mg/kg) on Gestation Day 8 to pregnanthamsters (4.7 to 43.5 times the HDD). A no adverse effect level was not defined in thisstudy and the findings cannot be clearly attributed to maternal toxicity. Neural tubedefects (exencephaly), axial skeletal fusions, and cryptorchidism were reported followinga single subcutaneous (SC) injection of morphine sulfate to pregnant mice (100-500mg/kg) on Gestation Day 8 or 9 at 200 mg/kg or greater (16 times the HDD) and fetalresorption at 400 mg/kg or higher (32 times the HDD). No adverse effects were notedfollowing 100 mg/kg morphine in this model (8 times the HDD). In one study, followingcontinuous subcutaneous infusion of doses greater than or equal to 2.72 mg/kg to mice(0.2 times the HDD), exencephaly, hydronephrosis, intestinal hemorrhage, splitsupraoccipital, malformed sternebrae, and malformed xiphoid were noted. The effectswere reduced with increasing daily dose; possibly due to rapid induction of toleranceunder these infusion conditions. The clinical significance of this report is not clear.Decreased fetal weights were observed in pregnant rats treated with 20 mg/kg/daymorphine sulfate (3.2 times the HDD) from Gestation Day 7 to 9. There was no evidenceof malformations despite maternal toxicity (10% mortality). In a second rat study,decreased fetal weight and increased incidences of growth retardation were noted at 35mg/kg/day (5.7 times the HDD) and there was a reduced number of fetuses at 70mg/kg/day (11.4 times the HDD) when pregnant rats were treated with 10, 35, or 70mg/kg/day morphine sulfate via continuous infusion from Gestation Day 5 to 20. Therewas no evidence of fetal malformations or maternal toxicity.An increased incidence of abortion was noted in a study in which pregnant rabbits weretreated with 2.5 (0.8 times the HDD) to 10 mg/kg morphine sulfate via subcutaneousinjection from Gestation Day 6 to 10. In a second study, decreased fetal body weights

were reported following treatment of pregnant rabbits with increasing doses ofmorphine (10-50 mg/kg/day) during the pre-mating period and 50 mg/kg/day (16 timesthe HDD) throughout the gestation period. No overt malformations were reported ineither publication; although only limited endpoints were evaluated.In published studies in rats, exposure to morphine during gestation and/or lactationperiods is associated with: decreased pup viability at 12.5 mg/kg/day or greater (2 timesthe HDD); decreased pup body weights at 15 mg/kg/day or greater (2.4 times the HDD);decreased litter size, decreased absolute brain and cerebellar weights, cyanosis, andhypothermia at 20 mg/kg/day (3.2 times the HDD); alteration of behavioral responses(play, social-interaction) at 1 mg/kg/day or greater (0.2 times the HDD); alteration ofmaternal behaviors (e.g., decreased nursing and pup retrievals) in mice at 1 mg/kg orhigher (0.08 times the HDD) and rats at 1.5 mg/kg/day or higher (0.2 times the HDD);and a host of behavioral abnormalities in the offspring of rats, including alteredresponsiveness to opioids at 4 mg/kg/day (0.7 times the HDD) or greater.Fetal and/or postnatal exposure to morphine in mice and rats has been shown to resultin morphological changes in fetal and neonatal brain and neuronal cell loss, alteration ofa number of neurotransmitter and neuromodulator systems, including opioid and non-opioid systems, and impairment in various learning and memory tests that appear topersist into adulthood. These studies were conducted with morphine treatment usuallyin the range of 4 to 20 mg/kg/day (0.7 to 3.2 times the HDD).Additionally, delayed sexual maturation and decreased sexual behaviors in femaleoffspring at 20 mg/kg/day (3.2 times the HDD), and decreased plasma and testicularlevels of luteinizing hormone and testosterone, decreased testes weights, seminiferoustubule shrinkage, germinal cell aplasia, and decreased spermatogenesis in male offspringwere also observed at 20 mg/kg/day (3.2 times the HDD). Decreased litter size andviability were observed in the offspring of male rats that were intraperitoneallyadministered morphine sulfate for 1 day prior to mating at 25 mg/kg/day (4.1 times theHDD) and mated to untreated females. Decreased viability and body weight and/ormovement deficits in both first and second generation offspring were reported whenmale mice were treated for 5 days with escalating doses of 120 to 240 mg/kg/daymorphine sulfate (9.7 to 19.5 times the HDD) or when female mice treated withescalating doses of 60 to 240 mg/kg/day (4.9 to 19.5 times the HDD) followed by a 5-day treatment-free recovery period prior to mating. Similar multigenerational findingswere also seen in female rats pre-gestationally treated with escalating doses of 10 to 22mg/kg/day morphine (1.6 to 3.6 times the HDD).8.2 LactationRisk SummaryMorphine is present in breast milk. Published lactation studies report variableconcentrations of morphine in breast milk with administration of immediate-releasemorphine to nursing mothers in the early postpartum period with a milk-to-plasmamorphine AUC ratio of 2.5:1 measured in one lactation study. However, there isinsufficient information to determine the effects of morphine on the breastfed infant andthe effects of morphine on milk production. Lactation studies have not been conductedwith MITIGO, and no information is available on the effects of the drug on the breastfedinfant or the effects of the drug on milk production.The developmental and health benefits of breastfeeding should be considered along with

the mother’s clinical need for MITIGO and any potential adverse effects on the breastfedinfant from MITIGO or from the underlying maternal condition.Clinical ConsiderationsMonitor infants exposed to MITIGO through breast milk for excess sedation andrespiratory depression. Withdrawal symptoms can occur in breastfed infants whenmaternal administration of morphine is stopped, or when breastfeeding is stopped.8.3 Females and Males of Reproductive PotentialInfertilityChronic use of opioids may cause reduced fertility in females and males of reproductivepotential. It is not known whether these effects on fertility are reversible [see AdverseReactions ( 6), Clinical Pharmacology ( 12.2)].In published animal studies, morphine administration adversely effected fertility andreproductive endpoints in male rats and prolonged estrus cycle in female rats [seeNonclinical Toxicology ( 13)].8.4 Pediatric UseAdequate studies to establish the safety and effectiveness of spinal morphine inpediatric patients have not been performed, and usage in this population is notrecommended.8.5 Geriatric UseElderly patients (aged 65 years or older) may have increased sensitivity to MITIGO. Ingeneral, use caution when selecting a dosage for an elderly patient, usually starting atthe low end of the dosing range, reflecting the greater frequency of decreased hepatic,renal, or cardiac function and of concomitant disease or other drug therapy.Respiratory depression is the chief risk for elderly patients treated with opioids, and hasoccurred after large initial doses were administered to patients who were not opioid-tolerant or when opioids were co-administered with other agents that depressrespiration. Titrate the dosage of MITIGO slowly in geriatric patients and monitor closelyfor signs of central nervous system and respiratory depression [see Warnings andPrecautions ( 5.8)].The pharmacodynamic effects of neuraxial morphine in the elderly are more variablethan in the younger population. Patients will vary widely in the effective initial dose, rateof development of tolerance and the frequency and magnitude of associated adverseeffects as the dose is increased. Initial doses should be based on careful clinicalobservation following “test doses”, after making due allowances for the effects of thepatient’s age and infirmity on his/her ability to clear the drug, particularly in patientsreceiving epidural morphine.Morphine is known to be substantially excreted by the kidney, and the risk of adversereactions to this drug may be greater in patients with impaired renal function. Becauseelderly patients are more likely to have decreased renal function, care should be taken indose selection, and it may be useful to monitor renal function.8.6 Hepatic or Renal ImpairmentThe elimination half-life of morphine may be prolonged in patients with reduced metabolic

rates and with hepatic and/or renal dysfunction. Hence, care should be exercised inadministering MITIGO epidurally to patients with these conditions. High blood morphinelevels, due to reduced clearance, may take several days to develop.

9 DRUG ABUSE AND DEPENDENCE9.1 Controlled SubstanceMITIGO contains morphine, a Schedule II controlled drug substance.9.2 AbuseMITIGO contains morphine, a substance with a high potential for abuse similar to otheropioids. MITIGO can be abused and is subject to misuse, addiction, and criminaldiversion [see Warnings and Precautions ( 5.3)].All patients treated with opioids require careful monitoring for signs of abuse andaddiction, because use of opioid analgesic products carries the risk of addiction evenunder appropriate medical use.Prescription drug abuse is the intentional non-therapeutic use of a prescription drug,even once, for its rewarding psychological or physiological effects.Drug addiction is a cluster of behavioral, cognitive, and physiological phenomena thatdevelop after repeated substance use and includes: a strong desire to take the drug,difficulties in controlling its use, persisting in its use despite harmful consequences, ahigher priority given to drug use than to other activities and obligations, increasedtolerance, and sometimes a physical withdrawal.“Drug-seeking” behavior is very common in persons with substance use disorders.Drug-seeking tactics include emergency calls or visits near the end of office hours,refusal to undergo appropriate examination, testing, or referral, repeated “loss” ofprescriptions, tampering with prescriptions, and reluctance to provide prior medicalrecords or contact information for other treating health care provider(s). “Doctorshopping” (visiting multiple prescribers to obtain additional prescriptions) is commonamong drug abusers and people suffering from untreated addiction. Preoccupation withachieving adequate pain relief can be appropriate behavior in a patient with poor paincontrol.Abuse and addiction are separate and distinct from physical dependence and tolerance.Healthcare providers should be aware that addiction may not be accompanied byconcurrent tolerance and symptoms of physical dependence in all addicts. In addition,abuse of opioids can occur in the absence of true addiction.MITIGO, like other opioids, can be diverted for non-medical use into illicit channels ofdistribution. Careful record-keeping of prescribing information, including quantity,frequency, and renewal requests, as required by state and federal law, is stronglyadvised.Proper assessment of the patient, proper prescribing practices, periodic re-evaluation oftherapy, and proper dispensing and storage are appropriate measures that help to limitabuse of opioid drugs.9.3 Dependence

Both tolerance and physical dependence can develop during chronic opioid therapy.Tolerance is the need for increasing doses of opioids to maintain a defined effect suchas analgesia (in the absence of disease progression or other external factors). Tolerancemay occur to both the desired and undesired effects of drugs, and may develop atdifferent rates for different effects.Physical dependence results in withdrawal symptoms after abrupt discontinuation or asignificant dosage reduction of a drug. Withdrawal also may be precipitated through theadministration of drugs with opioid antagonist activity (e.g., naloxone, nalmefene), mixedagonist/antagonist analgesics (e.g., pentazocine, butorphanol, nalbuphine), or partialagonists (e.g., buprenorphine). Physical dependence may not occur to a clinicallysignificant degree until after several days to weeks of continued opioid usage.MITIGO should not be abruptly discontinued [see Dosage and Administration ( 2.6)]. IfMITIGO is abruptly discontinued in a physically-dependent patient, a withdrawalsyndrome may occur. Some or all of the following can characterize this syndrome:restlessness, lacrimation, rhinorrhea, yawning, perspiration, chills, myalgia, andmydriasis. Other signs and symptoms also may develop, including: irritability, anxiety,backache, joint pain, weakness, abdominal cramps, insomnia, nausea, anorexia,vomiting, diarrhea, or increased blood pressure, respiratory rate, or heart rate.Infants born to mothers physically dependent on opioids will also be physicallydependent and may exhibit respiratory difficulties and withdrawal signs [see Use inSpecific Populations ( 8.1)].

10 OVERDOSAGEClinical PresentationAcute overdose with MITIGO can be manifested by respiratory depression, somnolenceprogressing to stupor or coma, skeletal muscle flaccidity, cold and clammy skin,constricted pupils, and, in some cases, pulmonary edema, bradycardia, hypotension,partial or complete airway obstruction, atypical snoring, and death. Marked mydriasisrather than miosis may be seen with hypoxia in overdose situations [See ClinicalPharmacology ( 12.2)].Treatment of OverdoseIn case of overdose, priorities are the reestablishment of a patent and protected airwayand institution of assisted or controlled ventilation, if needed. Employ other supportivemeasures (including oxygen and vasopressors) in the management of circulatory shockand pulmonary edema as indicated. Cardiac arrest or arrhythmias will require advancedlife-support techniques.The opioid antagonists, naloxone or nalmefene, are specific antidotes to respiratorydepression resulting from opioid overdose. For clinically significant respiratory orcirculatory depression secondary to morphine overdose, administer an opioidantagonist. Opioid antagonists should not be administered in the absence of clinicallysignificant respiratory or circulatory depression secondary to morphine overdose.As the duration of effect of naloxone is considerably shorter than that of epidural orintrathecal morphine, repeated administration may be necessary. Patients should beclosely observed for evidence of renarcotization.

Because the duration of opioid reversal is expected to be less than the duration ofaction of morphine in MITIGO, particularly with epidural or intrathecal morphine, carefullymonitor the patient until spontaneous respiration is reliably re-established. If theresponse to an opioid antagonist is suboptimal or only brief in nature, administeradditional antagonist as directed by the product’s prescribing information.In an individual physically dependent on opioids, administration of the recommendedusual dosage of the antagonist will precipitate an acute withdrawal syndrome. Theseverity of the withdrawal symptoms experienced will depend on the degree of physicaldependence and the dose of the antagonist administered. If a decision is made to treatserious respiratory depression in the physically dependent patient, administration of theantagonist should be begun with care and by titration with smaller than usual doses ofthe antagonist.

11 DESCRIPTIONMITIGO (morphine sulfate injection, USP – Preservative-free) is an opioid agonist,available as a sterile, nonpyrogenic, isobaric, high potency solution of morphine sulfate instrengths of 10 mg or 25 mg morphine sulfate per mL, free of antioxidants,preservatives or other potentially neurotoxic additives. MITIGO is intended for use incontinuous microinfusion devices for intraspinal administration in the management ofpain. Morphine is the most important alkaloid of opium and is a phenanthrene derivative.It is available as the sulfate salt, chemically identified as 7,8-Didehydro-4,5- epoxy-17-methyl-(5α,6α)-morphinan-3,6-diol sulfate (2:1) (salt), pentahydrate, with the followingstructural formula:

(C H NO ) • H SO • 5H O Molecular Weight = 758.83Morphine sulfate USP is an odorless, white crystalline powder with a bitter taste. It has asolubility of 1 in 21 parts of water and 1 in 1000 parts of alcohol, but is practicallyinsoluble in chloroform or ether. The octanol:water partition coefficient of morphine is1.42 at physiologic pH and the pKa is 7.9 for the tertiary nitrogen (the majority is ionizedat pH 7.4).Each mL of MITIGO 200 mg/20 mL contains morphine sulfate, USP 10 mg and sodiumchloride 8 mg in Water for Injection, USP. Each mL of MITIGO 500 mg/20 mL containsmorphine sulfate, USP 25 mg and sodium chloride 6.25 mg in Water for Injection, USP.

17 19 3 2 2 4 2

If needed, sodium hydroxide and/r sulfuric acid are added for pH adjustment to 4.5.Contains no preservative. Each 20mL vial of MITIGO is intended for SINGLE-DOSE ONLY.

12 CLINICAL PHARMACOLOGY12.1 Mechanism of ActionMorphine is a full opioid agonist and is relatively selective for the mu-opioid receptor,although it can bind to other opioid receptors at higher doses. The principal therapeuticaction of morphine is analgesia. Like all full opioid agonists, there is no ceiling effect foranalgesia with morphine. Clinically, dosage is titrated to provide adequate analgesia andmay be limited by adverse reactions, including respiratory and CNS depression.The precise mechanism of the analgesic action is unknown. However, specific CNSopioid receptors for endogenous compounds with opioid-like activity have been identifiedthroughout the brain and spinal cord and are thought to play a role in the analgesiceffects of this drug.12.2 PharmacodynamicsEffects on the Central Nervous SystemMorphine produces respiratory depression by direct action on brain stem respiratorycenters. The respiratory depression involves a reduction in the responsiveness of thebrain stem respiratory centers to both increases in carbon dioxide tension and electricalstimulation.Morphine causes miosis, even in total darkness. Pinpoint pupils are a sign of opioidoverdose but are not pathognomic (e.g., pontine lesions of hemorrhagic or ischemicorigins may produce similar findings). Marked mydriasis rather than miosis may be seendue to hypoxia in overdose situations.Both early and late respiratory depression (up to 24 hours post dosing) have beenreported following neuraxial administration. Circulation of the spinal fluid may also resultin high concentrations of morphine reaching the brain stem directly.Effects on the Gastrointestinal Tract and Other Smooth MuscleMorphine causes a reduction in motility associated with an increase in smooth muscletone in the antrum of the stomach and duodenum. Digestion of food in the smallintestine is delayed and propulsive contractions are decreased. Propulsive peristalticwaves in the colon are decreased, while tone may be increased to the point of spasm,resulting in constipation. Other opioid-induced effects may include a reduction in biliaryand pancreatic secretions, spasm of sphincter of Oddi, and transient elevations inserum amylase.Effects on the Cardiovascular SystemMorphine produces peripheral vasodilation which may result in orthostatic hypotensionor syncope. Manifestations of histamine release and/or peripheral vasodilation mayinclude pruritus, flushing, red eyes and sweating and/or orthostatic hypotension.Effects on the Endocrine SystemOpioids inhibit the secretion of adrenocorticotropic hormone (ACTH), cortisol, andluteinizing hormone (LH) in humans [See Adverse Reactions ( 6)]. They also stimulate

prolactin, growth hormone (GH) secretion, and pancreatic secretion of insulin andglucagon.Chronic use of opioids may influence the hypothalamic-pituitary-gonadal axis, leading toandrogen deficiency that may manifest as low libido, impotence, erectile dysfunction,amenorrhea, or infertility. The causal role of opioids in the clinical syndrome ofhypogonadism is unknown because the various medical, physical, lifestyle, andpsychological stressors that may influence gonadal hormone levels have not beenadequately controlled for in studies conducted to date [see Adverse Reactions ( 6)].Effects on the Immune SystemOpioids have been shown to have a variety of effects on components of the immunesystem in in vitro and animal models. The clinical significance of these findings isunknown. Overall, the effects of opioids appear to be modestly immunosuppressive.Concentration – Efficacy RelationshipsThe minimum effective analgesic concentration will vary widely among patients, especiallyamong patients who have been previously treated with potent agonist opioids. Theminimum effective analgesic concentration of morphine for any individual patient mayincrease over time due to an increase in pain, the development of a new pain syndromeand/or the development of analgesic tolerance [See Dosage and Administration ( 2.1)].Concentration – Adverse Reaction RelationshipsThere is a relationship between increasing morphine plasma concentration andincreasing frequency of dose-related opioid adverse reactions such as nausea, vomiting,CNS effects, and respiratory depression. In opioid-tolerant patients, the situation may bealtered by the development of tolerance to opioid-related adverse reactions [See Dosageand Administration ( 2.1, 2.2, 2.6)].12.3 PharmacokineticsEpidural AdministrationAbsorption

Morphine, injected into the epidural space, is rapidly absorbed into the generalcirculation. Absorption is so rapid that the plasma concentration-time profiles closelyresemble those obtained after intravenous or intramuscular administration. Peak plasmaconcentrations averaging 33–40 ng/mL (range 5–62 ng/mL) are achieved within 10 to 15minutes after administration of 3 mg of morphine.Distribution

Plasma concentrations decline in a multiexponential fashion. CSF concentrations ofmorphine, after epidural doses of 2 to 6 mg in postoperative patients, have beenreported to be 50 to 250 times higher than corresponding plasma concentrations. TheCSF levels of morphine exceed those in plasma after only 15 minutes and are detectablefor as long as 20 hours after the injection of 2 mg of epidural morphine. Approximately4% of the dose injected epidurally reaches the CSF. This corresponds to the relativeminimum effective epidural and intrathecal doses of 5 mg and 0.25 mg, respectively. Thedisposition of morphine in the CSF follows a biphasic pattern, with an early half-life of 1.5h and a late phase half-life of about 6 h. Morphine crosses the dura slowly, with anabsorption half-life across the dura averaging 22 minutes. Maximum CSF concentrations

are seen 60–90 minutes after injection. Minimum effective CSF concentrations forpostoperative analgesia average 150 ng/mL (range < 1380 ng/mL).Elimination

The terminal half-life is reported to range from 39 to 249 minutes (mean of 90 ± 34.3min) for epidural administration.Metabolism

The major pathway of clearance is hepatic glucuronidation to morphine-3-glucuronide,which is pharmacologically inactive.Excretion

The major excretion path of the morphine-3-glucuronide conjugate is through thekidneys, with about 10% in the feces. Morphine is also eliminated by the kidneys, 2 to12% being excreted unchanged in the urine.Intrathecal AdministrationAbsorption

Time-to-peak plasma concentrations, however, are similar (5-10 min) after eitherepidural or intrathecal bolus administration of morphine. Maximum plasma morphineconcentrations after 0.3 mg intrathecal morphine have been reported from < 1 to 7.8ng/mL. The minimum analgesic morphine plasma concentration during Patient ControlledAnalgesia (PCA) has been reported as 20–40 ng/mL, suggesting that any analgesiccontribution from systemic redistribution would be minimal after the first 30–60 minuteswith epidural administration and virtually absent with intrathecal administration ofmorphine.Distribution

The intrathecal route of administration circumvents meningeal diffusion barriers and,therefore, lower doses of morphine produce comparable analgesia to that induced bythe epidural route. After intrathecal bolus injection of morphine, there is a rapid initialdistribution phase lasting 15–30 minutes and a half-life in the CSF of 42–136 min (mean90 ± 16 min). Derived from limited data, it appears that the disposition of morphine inthe CSF, from 15 minutes post intrathecal administration to the end of a six-hourobservation period, represents a combination of the distribution and elimination phases.Morphine concentrations in the CSF averaged 332 ± 137 ng/mL at 6 hours, following abolus dose of 0.3 mg of morphine. The apparent volume of distribution of morphine inthe intrathecal space is about 22 ± 8 mL.

13 NONCLINICAL TOXICOLOGY13.1 Carcinogenesis, Mutagenesis, Impairment of FertilityCarcinogenesisLong-term studies in animals to evaluate the carcinogenic potential of morphine have notbeen conducted.MutagenesisNo formal studies to assess the mutagenic potential of morphine have been conducted.

In the published literature, morphine was found to be mutagenic in vitro increasing DNAfragmentation in human T-cells. Morphine was reported to be mutagenic in the in vivomouse micronucleus assay and positive for the induction of chromosomal aberrations inmouse spermatids and murine lymphocytes. Mechanistic studies suggest that the in vivoclastogenic effects reported with morphine in mice may be related to increases inglucocorticoid levels produced by morphine in this species. In contrast to the abovepositive findings, in vitro studies in the literature have also shown that morphine did notinduce chromosomal aberrations in human leukocytes or translocations or lethalmutations in Drosophila.Impairment of FertilityNo formal nonclinical studies to assess the potential of morphine to impair fertility havebeen conducted.Several nonclinical studies from the literature have demonstrated adverse effects onmale fertility in the rat from exposure to morphine. One study in which male rats wereadministered morphine sulfate subcutaneously prior to mating (up to 30 mg/kg twicedaily) and during mating (20 mg/kg twice daily) with untreated females, a number ofadverse reproductive effects including reduction in total pregnancies and higherincidence of pseudopregnancies at 20 mg/kg/day (3.2 times the HDD) were reported.Studies from the literature have also reported changes in hormonal levels in male rats(i.e. testosterone, luteinizing hormone) following treatment with morphine at 10mg/kg/day or greater (1.6 times the HDD).Female rats that were administered morphine sulfate intraperitoneally prior to matingexhibited prolonged estrous cycles at 10 mg/kg/day (1.6 times the HDD).

16 HOW SUPPLIED/STORAGE AND HANDLINGMITIGO (morphine sulfate injection, USP), is a preservative-free solution, supplied inamber vials for epidural or intrathecal administration via a continuous microinfusiondevice as follows:MITIGO 200 mg/20 mL (10 mg/mL) – NDC 66794-160-02: Single-Dose amber vialspackaged individuallyMITIGO 500 mg/20 mL (25 mg/mL) – NDC 66794-162-02: Single-Dose amber vialspackaged individuallyMITIGO is supplied in sealed vials. Accidental dermal exposure should be treated by theremoval of any contaminated clothing and rinsing the affected area with water.PROTECT FROM LIGHT. Keep stored in carton until time of use. Store at 20° - 25°C (68°- 77°F), excursions permitted to 15° - 30°C (59° - 86°F) [See USP Controlled RoomTemperature]. DO NOT FREEZE. MITIGO contains no preservative or antioxidant. Each20 mL vial of MITIGO is intended for SINGLE-DOSE ONLY. Discard any unused portion.Do not heat-sterilize.To report SUSPECTED ADVERSE REACTIONS, contact Piramal Critical Care,Inc. at 1-888-822-8431 or FDA at 1-800-FDA-1088 orwww.fda.gov/medwatch.For Product Inquiry call 1-888-822-8431.

17 PATIENT COUNSELING INFORMATIONAddiction, Abuse, and MisuseInform patients that the use of MITIGO, even when taken as recommended, can result inaddiction, abuse, and misuse, which can lead to overdose and death [see Warnings andPrecautions ( 5.3)]. Instruct patients not to share MITIGO with others and to take stepsto protect MITIGO from theft or misuse.Life-Threatening Respiratory DepressionInform patients of the risk of life-threatening respiratory depression, includinginformation that the risk is greatest when starting MITIGO or when the dosage isincreased, and that it can occur even at recommended dosages [see Warnings andPrecautions ( 5.2)]. Advise patients how to recognize respiratory depression and to seekmedical attention if breathing difficulties develop.Interactions with Benzodiazepines and Other CNS DepressantsInform patients and caregivers that potentially fatal additive effects may occur if MITIGOis used with benzodiazepines or other CNS depressants, including alcohol, and not touse these concomitantly unless supervised by a healthcare provider [see Warnings andPrecautions ( 5.5), Drug Interactions ( 7)].Serotonin SyndromeInform patients that MITIGO could cause a rare but potentially life-threatening conditionresulting from concomitant administration of serotonergic drugs. Warn patients of thesymptoms of serotonin syndrome and to seek medical attention right away if symptomsdevelop. Instruct patients to inform their physicians if they are taking, or plan to takeserotonergic medications [see Drug Interactions ( 7)].MAOI InteractionInform patients not to take MITIGO while using any drugs that inhibit monoamineoxidase. Patients should not start MAOIs while taking MITIGO [see Warnings andPrecautions ( 5.9), Drug Interactions ( 7)].HypotensionInform patients that MITIGO may cause orthostatic hypotension and syncope. Instructpatients how to recognize symptoms of low blood pressure and how to reduce the riskof serious consequences should hypotension occur (e.g., sit or lie down, carefully risefrom a sitting or lying position) [see Warnings and Precautions ( 5.11)].AnaphylaxisInform patients that anaphylaxis has been reported with ingredients contained inMITIGO. Advise patients how to recognize such a reaction and when to seek medicalattention [see Contraindications ( 4), Adverse Reactions ( 6)].PregnancyNeonatal Opioid Withdrawal Syndrome

Inform female patients of reproductive potential that prolonged use of MITIGO during

pregnancy can result in neonatal opioid withdrawal syndrome, which may be life-threatening if not recognized and treated [see Warnings and Precautions ( 5.4), Use inSpecific Populations ( 8.1)].Embryo-Fetal Toxicity

Inform female patients of reproductive potential that MITIGO can cause fetal harm andto inform the healthcare provider of a known or suspected pregnancy [see Use inSpecific Populations ( 8.3)].LactationAdvise nursing mothers to monitor infants for increased sleepiness (more than usual),breathing difficulties, or limpness. Instruct nursing mothers to seek immediate medicalcare if they notice these signs [see Use in Specific Populations ( 8.2)].InfertilityInform patients that chronic use of opioids may cause reduced fertility. It is not knownwhether these effects on fertility are reversible [see Adverse Reactions ( 6)].Driving or Operating Heavy MachineryInform patients that MITIGO may impair the ability to perform potentially hazardousactivities such as driving a car or operating heavy machinery. Advice patients not toperform such tasks until they know how they will react to the medication [see Warningsand Precautions ( 5.16)].ConstipationAdvise patients of the potential for severe constipation, including managementinstructions and when to seek medical attention [see Adverse Reactions ( 6)].Manufactured For:Piramal Critical CareBethlehem PA 18017 USA(888) 822-8431Issued 04/2021

PACKAGE LABEL.PRINCIPAL DISPLAY PANELNDC 66794-160-02MITIGOMorphine Sulfate Injection USP, CII200 mg/20 mL (10 mg/mL)NOT FOR IV, IM or SC INJECTIONFOR NEURAXIAL ADMINISTRATION INCONTINUOUS MICROINFUSION DEVICES20 mL Single Use Vial (Preservative-free)

NDC 66794-160-02MITIGOMorphine Sulfate Injection USP, CII200 mg/20 mL (10 mg/mL)NOT FOR IV, IM or SC INJECTIONFOR NEURAXIAL ADMINISTRATION INCONTINUOUS MICROINFUSION DEVICES20 mL Single Use Vial (Preservative-free)

NDC 66794-162-02MITIGOMorphine Sulfate Injection USP, CII500 mg/20 mL (25 mg/mL)NOT FOR IV, IM or SC INJECTION

FOR NEURAXIAL ADMINISTRATION INCONTINUOUS MICROINFUSION DEVICES20 mL Single Use Vial (Preservative-free)

NDC 66794-162-02MITIGOMorphine Sulfate Injection USP, CII500 mg/20 mL (25 mg/mL)NOT FOR IV, IM or SC INJECTIONFOR NEURAXIAL ADMINISTRATION INCONTINUOUS MICROINFUSION DEVICES20 mL Single Use Vial (Preservative-free)

MITIGO morphine sulfate injection

Product InformationProduct Type HUMAN PRESCRIPTION DRUG Item Code (Source) NDC:66794-160

Route of Administration EPIDURAL, INTRATHECAL DEA Schedule CII

Active Ingredient/Active MoietyIngredient Name Basis of Strength Strength

MORPHINE SULFATE (UNII: X3P646A2J0) (MORPHINE - UNII:76I7G6D29C) MORPHINE SULFATE 200 mg in 20 mL

Inactive IngredientsIngredient Name Strength

SODIUM CHLORIDE (UNII: 451W47IQ8X) SULFURIC ACID (UNII: O40UQP6WCF) WATER (UNII: 059QF0KO0R) SODIUM HYDROXIDE (UNII: 55X04QC32I)

Packaging# Item Code Package Description Marketing Start

DateMarketing End

Date1 NDC:66794-

160-021 mL in 1 VIAL, SINGLE-USE; Type 0: Not aCombination Product 02/25/2019

Marketing InformationMarketingCategory

Application Number or MonographCitation

Marketing StartDate

Marketing EndDate

ANDA ANDA204393 02/25/2019

MITIGO morphine sulfate injection

Product InformationProduct Type HUMAN PRESCRIPTION DRUG Item Code (Source) NDC:66794-162

Route of Administration EPIDURAL, INTRATHECAL DEA Schedule CII

Active Ingredient/Active MoietyIngredient Name Basis of Strength Strength

MORPHINE SULFATE (UNII: X3P646A2J0) (MORPHINE - UNII:76I7G6D29C) MORPHINE SULFATE 500 mg in 20 mL

Inactive IngredientsIngredient Name Strength

WATER (UNII: 059QF0KO0R) SULFURIC ACID (UNII: O40UQP6WCF) SODIUM CHLORIDE (UNII: 451W47IQ8X) SODIUM HYDROXIDE (UNII: 55X04QC32I)

Piramal Critical Care, Inc.

Packaging# Item Code Package Description Marketing Start

DateMarketing End

Date1 NDC:66794-

162-021 mL in 1 VIAL, SINGLE-USE; Type 0: Not aCombination Product 10/15/2018

Marketing InformationMarketingCategory

Application Number or MonographCitation

Marketing StartDate

Marketing EndDate

ANDA ANDA204393 10/15/2018

Labeler - Piramal Critical Care, Inc. (805600439)

Registrant - Piramal Critical Care, Inc. (805600439)

EstablishmentName Address ID/FEI Business Operations

PatheonManufacturingServices LLC

079415560 analys is(66794-160, 66794-162) , manufacture(66794-160, 66794-162) ,pack(66794-160, 66794-162) , label(66794-160, 66794-162)

Revised: 7/2021